Avadel pharmaceuticals to provide a corporate update and report first quarter 2021 financial results on may 10th

Dublin, ireland, april 29, 2021 (globe newswire) -- avadel pharmaceuticals plc (nasdaq: avdl), a company focused on developing ft218, an investigational, once-nightly formulation of sodium oxybate designed to treat excessive daytime sleepiness and cataplexy in patients with narcolepsy, announced today that it will host a conference call and live webcast at 8:30 a.m. et on monday, may 10, 2021, to provide a corporate update and discuss the company's financial results for the first quarter ended march 31, 2021.
AVDL Ratings Summary
AVDL Quant Ranking